PLX

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of medicines for patients with rare diseases. The company utilizes its proprietary ProCellEx® plant cell-based protein expression system and chemical and genetic modification capabilities, including PEGylation, to create recombinant therapeutic proteins. Protalix has two approved drugs and is expanding its pipeline to address unmet medical needs in rare diseases.